

ALPHABET SOUP OF ANTIMICROBIAL RESISTANCE

ANTIMICROBIAL RESISTANCE HOW CAN THE LAB HELP?

Dr. Susan Whittier, X 5-6281

ANTIBIOGRAM

- Antimicrobial susceptibility profile of pathogen
 - ✓ Guides empiric therapy based on intrinsic resistance patterns & predictable drug bug combinations
 - ✓ CAN YOU PROVIDE SOME EXAMPLES?
- Fickle pathogens
 - ✓ *S. maltophilia* & Trimeth/sulfa
 - ✓ *P. aeruginosa* & cipro
 - ✓ *K. pneumo* & imipenem
- Antibiogram NOW ON LINE!!
 - ✓ "Real-time" analysis
 - ✓ Make formulary decisions
 - ✓ Establish guidelines for antibiotic management

ANTIBIOTIC SUSCEPTIBILITY TESTING ROLE OF THE LAB

- FOLLOW CURRENT CLSI (NCCLS) GUIDELINES
- WHAT DRUGS SHOULD BE TESTED & REPORTED?
 - ✓ SELECTIVE DRUG/BUG COMBINATIONS BASED ON IN VIVO & IN VITRO CORRELATION OF DATA
 - ✓ ID, PHARM & CLINICAL MICRO TEAM
- ANNUAL ANTI-BIOGRAMS
 - ✓ HELPS WITH MICROBES WITH PREDICTABLE RESISTANCE PATTERNS
- LAB REPORTING SYSTEMS
 - ✓ SIR, YES/NO (DISK DIFFUSION)
 - ✓ MIC (DISK GRADIENT &/OR MICRODILUTION)
- TESTING NEW ANTIMICROBIAL AGENTS
 - ✓ JUST SIR BY DISK DIFFUSION
 - ✓ MIC BY DISK GRADIENT STRIP

ANTIBIOTIC SUSCEPTIBILITY TESTS

- MIC VALUE
 - ✓ LOWEST CONCENTRATION OF ANTIMICROBIAL WHICH WILL INHIBIT GROWTH
 - ✓ MICROSCAN or VITEK SEMIAUTOMATED
 - ✓ E-STRIPS (DISK GRADIENT)
 - ✓ TIME TO RESULTS: 18 - 24 HRS
- YES SIR, NO MIC
 - ✓ QUALITATIVE INTERPRETATION
 - ✓ DISK DIFFUSION (KIRBY-BAUER)
 - ✓ TIME TO RESULTS: 18 - 24 HRS
- QUESTIONS TO ASK.....
 - ✓ *S.aureus* IS ERYTHRO RESISTANT
 - IS IT A PREDICTOR OF CLINDA RESISTANCE?
 - ✓ LAB REPORTS PENICILLIN RESISTANT GP A STREP
 - IS THIS BELIEVABLE?
 - ✓ LAB REPORTS YEAST FROM BLOOD CULTURE
 - WHAT EMPIRIC TREATMENT IS RECOMMENDED?

WHAT AFFECTS CHOICE OF ANTIMICROBIAL AGENTS ?

- ANTIMICROBIAL SUSCEPTIBILITY TEST RESULTS
- PHARMACODYNAMICS
 - ✓ AUC:MIC₉₀ RATIO
 - ✓ HALF LIFE OF DRUG
 - ✓ TIME ABOVE THE MIC
 - ✓ CONCENTRATION DEPENDENT KILLING
 - Greater cidal activity with higher concen (e.g. aminoglycosides, B-lactams)

NAME CALLING AST JARGON

- MRSA - Methicillin-Resistant *S.aureus*
 - ✓ 44% at CUMC
- VISA- Vanco-intermediate *S. aureus*
- VRSA- Vanco-resistant *S. aureus*
- VRE- Vanco R *E. faecium*
 - ✓ 81% in CUMC
- ESBLs in GNR
 - ✓ 18% in CUMC

PREDICTABLE RESISTANCE

- **Salmonella, Shigella**
 - ✓ Stool: Ampicillin, quinolone, T/S ONLY will be reported
 - ✓ Extraintestinal: above + chloramphenicol, 3rd gen cephalosporin
- **Enterobacter, Serratia**
 - ✓ Ampicillin & 1st & 2nd generation cephalosporins are NOT reported
 - ✓ Routine resistance
- **Stenotrophomonas**
 - ✓ Inherent resistance to nearly all antimicrobics
 - ✓ ONLY T/S, Timentin & fluoroquinolone are reported
- **Campylobacter, Bacillus, Corynebacterium**
 - ✓ NO ESTABLISHED CRITERIA
- **Enterococcus**
 - ✓ Cephalosporins, aminoglycosides, clinda, T/S will NOT be reported

ENDOCARDITIS CASE MIC VALUES

- | | |
|--|--|
| <ul style="list-style-type: none"> ▪ ISOLATE #1 <ul style="list-style-type: none"> ✓ OXACILLIN 0.5 Resistant ✓ PENICILLIN 1.0 Resistant ✓ VANCO 1.0 Susceptible ✓ CLINDA ≤0.25 Susceptible ✓ ERYTHRO ≤ 0.25 Susceptible | <ul style="list-style-type: none"> ▪ ISOLATE #2 <ul style="list-style-type: none"> ✓ OXACILLIN 1.0 Resistant ✓ PENICILLIN 0.5 Resistant ✓ VANCO 0.5 Susceptible ✓ CLINDA ≤0.25 Susceptible ✓ ERYTHRO ≤ 0.25 Susceptible |
|--|--|

ARE THESE THE SAME ISOLATE? MICS WITHIN 1 2-FOLD DILUTION OF EACH OTHER ARE CONSIDERED THE SAME

THE "USED TO BE" PREDICTABLE AST PATTERNS

ORGANISMS	PREDICTABLE [Not so much...]
▪ <i>K. pneumo</i>	Susceptible to Imipenem
▪ <i>P. aeruginosa</i>	Susceptible to Cipro
▪ <i>Salmonella</i>	Susceptible to Cipro
▪ <i>S. aureus</i>	Susceptible to Vanco
▪ <i>E. faecium</i>	Susceptible to Linezolid
▪ Any organism	Susceptible to at least one antibiotic

ENDOCARDITIS CASE POINTS TO PONDER

- ARE THE ISOLATES REALLY RESISTANT?
 - ✓ MICS ARE VERY LOW [0.5 AND 1.0]
 - ✓ *S. AUREUS* OXACILLIN RESISTANCE ≥ 4
 - ✓ BREAKPOINTS FOR CNS & OXACILLIN WERE REVISED
 - ✓ MANY CNS STRAINS CONTAINED *MECA* BUT HAD OXACILLIN MICS BELOW THE 4 UG/ML BREAKPOINT
 - ✓ NOW THERE ARE TWO SETS OF OXACILLIN BREAKPOINTS

	SUS	RES
SA	≤ 2	≥ 4
CNS	≤ 0.25	≥ 0.5

ENDOCARDITIS CASE

- 61 yo male with persistent fevers
- Suspected subacute bacterial endocarditis
- Two sets of blood cultures collected
- Positive the next day for coagulase negative *Staphylococcus*
- AST panels are set up for isolates 1 & 2

ENDOCARDITIS CASE ONE MORE WRINKLE!

- ONE SPECIES OF CNS UTILIZES THE *S. AUREUS* BREAKPOINTS
 - ✓ *Staphylococcus lugdenensis*

Ubiquitous to skin & mucous membranes
 Portal of entry often unidentified
 Chronic renal failure
 Neoplastic disease
 Post-pneumonia
 High mortality associated with aggressive destruction of native valve

Staphylococcus lugdenensis

- Able to bind vitronectin & fibrinogen to extracellular matrix proteins
- Produces a delta-like toxin similar to that of *S. aureus*
- Demonstrate nucleic acid sequences related to SA accessory gene regulator (*agr*), a determinant of virulence
- Frequently emboligenic
- All traits are more typical of *S. aureus*

Beta-hemolytic *Streptococci*** Erythromycin/Clindamycin

MECHANISM	DETERMINANT	ERY	CLIN
EFFLUX	<i>MEF</i>	R	S
RIBOSOME MODIFICATION	<i>ERM</i>	R	S**
RIBOSOME MODIFICATION	<i>ERM</i>	R	R CONSTITU TIVE

* Groups A, B, C, G

**Requires induction to show resistance

65

NEONATAL SEPSIS

- Female full-term neonate developed fever of 103 at 2 days of age
- Irritable & not feeding well
- Mom's pre-natal screen at 36 wks gestation was positive for Grp B strep
 - ✓ MOM WAS PEN ALLERGIC SO RECEIVED IV CLINDAMYCIN DURING DELIVERY
 - ✓ PREGNANCY UNEVENTFUL OTHER THAN PROM @ 20H PRIOR TO DELIVERY
- Blood cultures collected from neonate & prophylactic ceftriaxone was initiated
- Signs of improvement w/in 6 hrs

BETA-HEMOLYTIC *STREPTOCOCCUS* RESISTANCE RATES (USA)*

- Beta-hemolytic *Streptococcus* spp.
 - ✓ AMPICILLIN / PENICILLIN / VANCOMYCIN: 0%
- Group A
 - ✓ ERYTHROMYCIN: UP TO 10%
 - ✓ CLINDAMYCIN: UP TO 7%
- Group B
 - ✓ ERYTHROMYCIN: UP TO 25%
 - ✓ CLINDAMYCIN: UP TO 15%

*commonly quoted rates; select studies may have reported higher rates

73

NEONATAL SEPSIS

- NEXT DAY, BLOOD CULTURES WERE POSITIVE FOR:
 - ✓ GPC chains & pairs
- DAY 2
 - ✓ Catalase negative
 - ✓ Beta hemolytic
 - ✓ Grp B strep latex positive
- AST Results
 - ✓ Ampicillin ≤ 0.25 Susceptible
 - ✓ Ceftriaxone ≤ 0.12 Susceptible
 - ✓ Clinda ≤ 0.25 Susceptible
 - ✓ Erythro >1 Resistant
 - ✓ Penicillin ≤ 0.12 Susceptible
 - ✓ Vanco ≤ 0.5 Susceptible

WHY WAS CLINDA NOT EFFECTIVE IN PREVENTING THIS INFECTION?

When the pieces of the puzzle don't quite fit....

- URINE CULTURE OBTAINED FROM LONG-TERM-CARE FACILITY PT
 - ✓ Patient hx significant for diabetes, peripheral vascular disease & chronic renal failure
- CULTURE RESULTS:
 - ✓ $>100,000$ CFU/ml *Staphylococcus aureus*


OXACILLIN	4	RESISTANT
CHLORAMPHENICOL	4	SUSCEPTIBLE
LINEZOLID	2	SUSCEPTIBLE
RIFAMPIN	1	SUSCEPTIBLE
TRIMETH/SULFA	2/38	SUSCEPTIBLE
VANCOMYCIN	4	SUSCEPTIBLE

PUZZLE PIECES

- Patient was started on vancomycin
- Urine cultures remained positive for *S. aureus*
- Further testing by lab
 - ✓ E test MIC = >256 RESISTANT!!
- Isolate was positive for
 - ✓ *mecA* OXACILLIN RESISTANCE
 - ✓ *vanA* VANCOMYCIN RESISTANCE MECHANISM FROM VRE
- WHAT HAPPENED???????
- Automated systems are unable to detect VRSA
- CDC recommends utilization of vancomycin screen agar plate

VRSA JUNE 2002

- 1st case in 40 yr old diabetic woman from Michigan
- VRSA from dialysis cath tip
- Recurrent foot ulcer infected with VRE & MRSA



VRSA

(3 isolates encountered to date)

Isolate	Vanco MIC ¹ (µg/ml)
1	1,024
2	32 ²
3	64 ²

¹ Reference broth microdilution MIC

² Missed or inconsistent results (some < 2 µg/ml) with automated methods

4/04 CDC RECOMMENDATION:
ADD VANCOMYCIN AGAR SCREEN WITH AUTOMATED METHOD

57

VISA

- VISA- INTERMEDIATE TO VANCO
 - ✓ 1ST ISOLATED IN 1996 IN JAPAN
 - ✓ 8 PTS TO DATE IN USA
 - ✓ MECHANISM OF RESISTANCE: THICKENED CELL WALL AND/OR AN EXTRACELLULAR MATRIX ??
 - ✓ PATIENTS HAD PRIOR EXPOSURE TO LONG TERM VANCOMYCIN THERAPY
- 2 VISA ISOLATES FOUND SUSCEPTIBLE TO OXACILLIN
 - ✓ ONE WAS *MECA* POS & ONE NEG
 - ✓ OXACILLIN RESISTANCE IS NOT NECESSARY FOR VISA PHENOTYPE
- NO CLONAL SPREAD OF SINGLE STRAIN

NEW TESTS

- LATEX AGGLUTINATION ASSAY
 - ✓ *PBP2a* low-affinity penicillin binding protein
 - ✓ Latex beads sensitized with monoclonal Ab vs *PBP2a*
 - ✓ PURE CULTURE ONLY (NOT SPECIMEN)
 - Need 10⁹ cells
 - ✓ 1 HR TEST
- PCR - GOLD STANDARD
 - ✓ *mecA* & *nuc* genes - COAMPLIFICATION
 - ✓ BLOOD CULTURE BOTTLES or PURE CULTURE
 - ✓ LYSE CELLS
 - ✓ SMART CYCLER (amplification & detection)
 - ✓ UNSTANDARDIZED
 - ✓ EXPENSIVE, TECHNICALLY CHALLENGING
 - ✓ 4 HR TEST

ICU SEPSIS

- 64 yo male patient, cardiac ICU post-CABG
- Becomes febrile and hemodynamically unstable
- Blood cultures x 2 are collected

Culture Results:

Klebsiella pneumoniae

Amikacin	8	S
Cefoxitin	4	S
Ceftazidime	≥32	R
Ceftriaxone	8	S
Imipenem	4	S

•Based on AST, patient treated w/ ceftriaxone

•Remains febrile

•Blood cultures collected

•Positive for *K. pneumoniae*


•What's going on?

ESBL PHENOTYPIC CONFIRMATORY TESTS

- To confirm screening results, compare the MIC values of:

- Ceftazidime to ceftazidime+clavulanate
- Cefotaxime to cefotaxime+clavulanate

- ESBL = ≥3 DOUBLING DILUTION DECREASE FOR EITHER DRUG IN THE PRESENCE OF CLAVULANATE



EXTENDED SPECTRUM β-LACTAMASES

- FIRST DESCRIBED IN 1983
- ESBLs ARE β-LACTAMASES THAT MEDIATE R TO
 - 3RD GEN CEPHALOSPORINS BUT THESE CAN APPEAR SUSCEPTIBLE WHEN TESTED IN LAB
 - MONOBACTAMS (E.G. AZTREONAM)
 - EXTENDED SPECTRUM PENICILLINS (E.G. PIPERACILLIN)
- STRUCTURAL GENES
 - PLASMID-MEDIATED
 - Altered configuration of TEM-1 & 2, SHV-1 near active sites to increase hydrolytic ability for cephalosporins
 - Susceptible to cefoxitin (cephamycin), β-lactamase inhibitors (but enzyme hyperproduction might overwhelm inhibitors)
 - Susceptible to carbapenems
 - CHROMOSOME-MEDIATED AMP C
 - AmpC in SPICE (*Serratia, Pseudo, Proteus, Citro, Enterobacter*)
 - PLASMID-MEDIATED AMP C
 - K1 in *K. oxytoca*
 - Resistant to cefoxitin (cephamycin) & β-lactamase inhibitors

You “Pneumo” Than You Thought

- A 35 year old obese female was admitted for elective knee replacement surgery following an automobile accident
- Post-surgery she developed ARDS and was placed on a ventilator
- The patient's condition continued to deteriorate and she developed a nosocomial pneumonia

KLEBSIELLA PNEUMONIAE TYPICAL ESBL AST PATTERN

Amikacin	8	S
Ampicillin	≥32	R
Cefoxitin	4	S
Cefazolin	≥32	R
Ceftazidime	≥32	R
Ciprofloxacin	≤1	S
Gentamicin	≥8	R
Imipenem	≤4	S
Piperacillin/Tazobactam	8/2	S
Aztreonam (monobactam)	≥32	R
Trimethoprim/Sulfamethoxazole	8/152	R

You “Pneumo” Than You Thought

- The antimicrobial susceptibility pattern of the isolate was as follows:
- Resistant to: ampicillin, piperacillin, amoxicillin-clavulanate, ampicillin-sulbactam, piperacillin-tazobactam, aztreonam, cefazolin, cefuroxime, cefotetan, ceftriaxone, cefotaxime, ceftazidime, cefepime, imipenem, meropenem, gentamicin, tobramycin, levofloxacin, ciprofloxacin, and trimethoprim-sulfamethoxazole
- Intermediate susceptibility to: amikacin
- Susceptible to: tetracycline

You “Pneumo” Than You Thought

- What gram-negative was recovered from BAL, an empyema collection, urine, and blood?
- *Klebsiella pneumoniae*

You “Pneumo” Than You Thought

- At least three mechanisms described that result in imipenem resistance among strains of *K. pneumoniae* among isolates recovered from patients in New York City
 - ✓ ampC hyperproduction with concomitant loss of outer membrane porins
 - ✓ KPC-2
 - ✓ KPC-3

You “Pneumo” Than You Thought

- What additional antibiotics might be tested?
- Polymyxin B: disk diffusion
 - ✓ zone size = 12 mm
 - ✓ Interpretation?

The Case of the Flavorful Bacterium

- A 30 day old male was seen by his pediatrician as an outpatient for routine circumcision
- The following day the mother noted a fever and brought the child to the emergency department of a rural hospital
- The child was admitted with a temperature of 103°F and started empirically on ampicillin and cefotaxime after collection of blood cultures and performance of a spinal tap due to “meningeal signs”
- Bladder catheterization was attempted but the tubing crimped and could not be properly placed or removed

You “Pneumo” Than You Thought

- Clinical isolates should not be tested for susceptibility to polymyxin B by the disk diffusion technique (Susceptible > 11 mm)
 - ✓ Large molecule; diffuses slowly
 - ✓ Poor correlation with MICs
 - ✓ QC ranges too large to be meaningful
 - ✓ MIC testing by E-test
 - ✓ The susceptibility testing breakpoints for polymyxin B are:
 - Susceptible ≤ 2 µg/mL
 - Resistant ≥ 4 µg/mL

A Bladder Case I have Never Seen

- The child was transferred emergently to CUMC for catheter removal and treatment of infection
- Blood cultures became positive at the outlying hospital with a gram-negative rod
- Upon admission to CUMC blood cultures were again collected, a 2nd spinal tap was performed, and cotrimoxazole was added to the antibiotic regimen
- Colonies had a very faint yellowish pigment; identified at the outside hospital using API NF-ID as a *Chryseobacterium* sp.

Chryseobacterium meningosepticum

- Isolates recovered both from CSF and blood at CUMC were identified as *C. meningosepticum*
- Natural habitats: soil, plants, foodstuffs, and water sources (including hospital)
- Oxidase and indole positive; nonmotile
- The patient was not responding optimally to therapy
- Pending results of antimicrobial susceptibility testing what changes were made to the antibiotic regimen?

Water Case This Was!

- Blood cultures were collected and the patient was admitted to the PICU
- He was started empirically on cefepime plus vancomycin
- The following day one of the two blood cultures became positive (aerobic bottle only) with a "diphtheroid" which was deemed a contaminant
- The young man responding to has antibiotics defervesced and his cellulitis felt less warm to the touch

Chryseobacterium meningosepticum

- *Chryseobacterium* spp. are inherently resistant to many antibiotics commonly used to treat infections caused by gram-negative bacteria (aminoglycosides, β -lactams, tetracyclines, and chloramphenicol)
- Susceptible to agents generally used for treating infections caused by gram-positive bacteria (rifampin, clindamycin, erythromycin, levofloxacin, trimethoprim-sulfamethoxazole, and vancomycin)
- Di Pentima et al (1998; CID; 26:1169-1176) provided evidence that IV vancomycin plus rifampin are appropriate empiric therapy for *C. meningosepticum* meningitis in newborns

Water Case This Was!

- The following morning the second blood culture became positive with the same "diphtheroid"
- Colonies developed a yellow pigment over a 3 day period of time
- The pediatric ID physician requested that the isolate be further identified and that antimicrobial susceptibility testing be performed
- Any thoughts as to the identity of the isolate?

"Water" Case This Was!

- A fifteen year old male just completing a course of methotrexate therapy for osteogenic sarcoma visited Myrtle Beach with his family
- While walking on the shore he stepped on a razor clam and sustained a cut to the bottom of his foot
- The following morning he noticed redness around the cut and treated it with triple ointment
- Upon returning home he presented to the ED with a cellulitis and low grade fever

Leifsonia aquatica

- Previously named *Corynebacterium aquaticum*
- Rarely encountered in clinical specimens
- Identity confirmed by NYC DOH
- Always motile; very strong DNase activity
- Yellow pigment of colonies develops slowly over three to four days
- Vancomycin MICs for some strains are elevated (8 μ g/mL)

How to Perform Susceptibility Tests?

- No NCCLS recommended methods for testing of coryneform bacteria (orphan organisms)
- No FDA or NCCLS breakpoints for interpreting results of MIC testing
- No disk diffusion interpretive criteria
- Three options
 - ✓ Do not test
 - ✓ Test and use breakpoints from other gram-positives
 - ✓ Test and report MIC results with no interpretations using PK to judge whether achievable levels can be reached at the site of infection

How “Sporing” Can a Case Get?

- Susceptibility testing is requested
- Which of the following approaches should be taken?
 - ✓ Set up disk diffusion tests?
 - ✓ Set up E-tests on Blood M-H?
 - ✓ Set up broth macrodilution testing in Mueller-Hinton (M-H) broth?
 - ✓ Go to literature and/or textbooks to assess published results?
 - ✓ Use NCCLS guidelines for testing of *B. anthracis*?

You’ll Take a “Lichen” to This Case

- A 5 year old boy with ALL with an indwelling intravascular line for administration of chemotherapeutic agents becomes febrile
- Redness and purulent discharge are noted at the line insertion site
- Blood cultures yield *Bacillus licheniformis*
- The child is treated empirically with ceftriaxone, defervesces, and clears his blood cultures

Bacillus spp.

- No correct/incorrect answers
- In Table 2K of M100-S14 it states: “Criteria for *B. anthracis* do not apply to other *Bacillus* spp.”
- Suggest using inoculum and incubation conditions listed in Table 2K and reporting MIC values without interpretations (unless result is > highest value tested; report as R)

I’m Not Giving You a ‘Line’

- Because of poor access, the vascular line is not removed
- 48 hours after cessation of therapy the child again shows signs of sepsis and additional blood cultures are collected
- Cultures again yield *B. licheniformis*
- Possible explanations?

Bacillus spp.

- Usually resistant to β -lactams
- Vancomycin and clindamycin recommended pending availability of susceptibility testing results
- Cephalosporins contraindicated
- Ciprofloxacin has been successfully used

TO THE RESCUE?

- **NEW ANTIBIOTICS**
 - ✓ **LINEZOLID**
 - ✓ **SYNERCID**
 - ✓ **DAPTOMYCIN**
 - ✓ **ERTAPENEM**
 - ✓ **TIGECYCLINE**
- **BACK FOR A 2ND CHANCE!**
 - ✓ **COLISTIN**
 - ✓ **POLYMYXIN B**

SYNERGY TESTING A NEW PLAN OF ATTACK!

- **CHOOSE TWO ANTIBIOTICS WITH DIFFERENT MECHANISMS OF ACTION**
- **COMBINE THEM TO SEE WHETHER THEY ARE MORE EFFECTIVE IN COMBINATION THAN EITHER IS INDIVIDUALLY**
- **HISTORICALLY EFFECTIVE**
 - ✓ **I.E. PENICILLIN & GENTAMYCIN FOR ENTEROCOCCI**
- **CLINICAL OUTCOME DATA SUPPORTS SYNERGY TESTING FOR:**
 - ✓ **GRAM NEGATIVE INFECTIONS IN NEUTROPENICS**
 - ✓ **CYSTIC FIBROSIS ISOLATES**
 - ✓ **PAN-RESISTANT GRAM NEGATIVES**
- **DETERMINE FIC (FRACTIONARY INHIBITORY CONCENTRATION)**

✓ SYNERGISTIC ✓ ADDITIVE ✓ ANTAGONISTIC